Results 191 to 200 of about 265,306 (275)

Reactive Arthritis Following Vaccination against COVID-19: An Unexpected Adverse Reaction. [PDF]

open access: yesIndian Dermatol Online J, 2023
Agrawal D, Sinha S, Dabas S, Malhotra P.
europepmc   +1 more source

Reactive Arthritis Following Coronavirus 2019 Infection in a Pediatric Patient: A Rare Case Report. [PDF]

open access: yesJ Hand Surg Glob Online, 2023
Daher J   +4 more
europepmc   +1 more source

Prothrombotic Activation of Platelet Pannexin‐1 Channels in Antiphospholipid Syndrome

open access: yesArthritis &Rheumatology, EarlyView.
Objective ATP is released from platelets through both degranulation and pannexin‐1 (PANX1) channels. ATP then activates P2X receptors to amplify platelet activation via calcium‐dependent signaling. The objective of this study was to evaluate the role of platelet PANX1 channels in the pathophysiology of antiphospholipid syndrome (APS), an acquired ...
Bruna de Moraes Mazetto Fonseca   +13 more
wiley   +1 more source

Single‐Cell RNA Sequencing Informs Precision Targeting of Monogenic Lupus Associated With IKZF1 Haploinsufficiency

open access: yesArthritis &Rheumatology, EarlyView.
Objective This study aimed to investigate the mechanisms of immune dysregulation in a pediatric patient with monogenic lupus driven by IKZF1 haploinsufficiency. Methods Peripheral immune cells from a patient with IKZF1 haploinsufficiency, patients with lupus with no currently known genetic mutations, and healthy controls were analyzed using single‐cell
Qi Zheng   +6 more
wiley   +1 more source

Nationwide Temporal Trends in Adverse Pregnancy Outcomes and Treatments in Systemic Lupus Erythematosus Pregnancy Over Two Decades in Sweden

open access: yesArthritis &Rheumatology, EarlyView.
Objective This nationwide descriptive study examined temporal trends in adverse pregnancy outcomes (APOs) and treatments in systemic lupus erythematosus (SLE) pregnancies in Sweden over 2003 to 2022. Methods Using nationwide Swedish registers, we identified 1,417 pregnancies of women with prevalent SLE and delivery dates in 2003 to 2022 and matched ...
Ngoc V. Nguyen   +6 more
wiley   +1 more source

Plasma Proteomics Identifies Thousand‐and‐One–Amino Acid Kinase 3 as a Potential Biomarker of Rheumatoid Arthritis Activity and a Novel Therapeutic Target

open access: yesArthritis &Rheumatology, EarlyView.
Objective Bone destruction associated with active rheumatoid arthritis (RA) remains a major therapeutic challenge, with a lack of reliable molecular markers reflecting bone injury. This study aims to identify novel biomarkers linked to bone destruction in active RA through proteomic analysis, providing new strategies for precise monitoring and targeted
Pengfei Xin   +15 more
wiley   +1 more source

Interleukin‐18 Levels Are Associated With Disease Course in Patients With Still Disease Treated With Interleukin‐1 Inhibitors

open access: yesArthritis &Rheumatology, EarlyView.
Objective To evaluate the prognostic utility of circulating interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in patients with Still disease (SD) receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan   +8 more
wiley   +1 more source

Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab

open access: yesArthritis &Rheumatology, EarlyView.
Objective The objective of the study was to determine risk factors for relapse of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) after reinduction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post hoc analysis of the RITAZAREM clinical trial.
Ellen Romich   +62 more
wiley   +1 more source

Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database

open access: yesArthritis &Rheumatology, EarlyView.
Objective The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear.
Corrado Campochiaro   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy